Get the Stockscreener App
9.6196
3.97%
0.3596
Overview
News
Price History
Option Chain
Financials
Why BHC Down?
Discussions
Forecast
Stock Split
Dividend History
Bausch Health Companies Inc stock is traded at $9.6196, with a volume of 758.64K.
It is up +3.97% in the last 24 hours and up +15.71% over the past month.
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
See More
Previous Close:
$9.26
Open:
$9.26
24h Volume:
758.64K
Relative Volume:
0.36
Market Cap:
$3.52B
Revenue:
$9.20B
Net Income/Loss:
$-471.00M
P/E Ratio:
-3.6438
EPS:
-2.64
Net Cash Flow:
$911.00M
1W Performance:
+17.98%
1M Performance:
+15.71%
6M Performance:
+23.11%
1Y Performance:
+27.18%
1-Day Range:
$9.17
$9.67
1-Week Range:
$8.09
$9.85
52-Week Range:
$3.96
$11.46
Bausch Health Companies Inc Stock (BHC) Company Profile
Name
Bausch Health Companies Inc
Sector
Phone
514-744-6792
Address
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-20-23 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Jul-29-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-29-22 | Downgrade | Truist | Buy → Hold |
| Jul-28-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-13-22 | Resumed | JP Morgan | Overweight |
| Mar-24-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-17-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-22-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-17-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-24-20 | Initiated | Citigroup | Buy |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-22-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-02-19 | Initiated | Goldman | Neutral |
| Oct-25-19 | Initiated | Cowen | Outperform |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Aug-15-19 | Upgrade | TD Securities | Hold → Buy |
| Jul-19-19 | Initiated | Wolfe Research | Outperform |
| Jun-11-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Jan-02-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Nov-05-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-18 | Upgrade | Piper Jaffray | Underweight → Neutral |
View All
Bausch Health Companies Inc Stock (BHC) Latest News
Intact Investment Management Inc. Acquires Shares of 189,000 Bausch Health Companies Inc. (NYSE:BHC) - MarketBeat
Bausch Health Companies' SWOT analysis: debt woes cloud strong Q3 stock performance - Investing.com
Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales - MSN
Bausch Health Companies Inc. (NYSE:BHC) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Bausch Health secures $400 million loan amendment - Investing.com
Bausch Health secures $400 million loan amendment By Investing.com - Investing.com UK
Bausch Health Companies (NYSE:BHC) Price Target Raised to $11.00 at Royal Bank of Canada - MarketBeat
Bausch Health Companies Inc. (NYSE:BHC) Q3 2024 Earnings Call Transcript - Insider Monkey
Bausch Health Companies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Bausch Health stock outlook lifted as RBC cites robust Q3 growth and tax benefits - Investing.com
Investors Purchase High Volume of Bausch Health Companies Put Options (NYSE:BHC) - MarketBeat
Toronto Stocks Drop, Canada's GDP Flat in August; Bausch Health Rises on 3Q Beat - Marketscreener.com
Bausch Health Shares Rise on FY Outlook Upgrade, 3Q Beat - MarketWatch
Bausch Health Companies (NYSE:BHC) Trading 8.7% Higher on Better-Than-Expected Earnings - MarketBeat
Bausch Health Companies (TSE:BHC) Stock Price Up 8.4% After Strong Earnings - MarketBeat
BHCBausch Health Companies Inc. Latest Stock News & Market Updates - StockTitan
Bausch: Q3 Earnings Snapshot - Houston Chronicle
Bausch Health Reports Growth Amid Improved Financials - TipRanks
Compared to Estimates, Bausch (BHC) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Bausch Health (BHC) Beats Q3 Earnings and Revenue Estimates - Yahoo Finance
Bausch Health Companies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Bausch Health Announces Third Quarter 2024 Results - AccessWire
Gastroparesis Treatment Market Top Trends and Growth Analysis: - openPR
Bausch Health Companies Q3 2024 Earnings Preview - MSN
Onychomycosis Treatment Market Size, Industry Analysis, - openPR
Actinic Keratosis Treatment Market Expected to Reach Huge - openPR
Canada Aesthetic Devices Market Size, Share, Industry Growth, - openPR
Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking - Marketscreener.com
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence - AccessWire
TD COWEN Downgrades Bausch Health Companies (BHC) - MSN
Bausch Health Companies (NYSE:BHC) Lifted to "Buy" at StockNews.com - MarketBeat
FY2024 EPS Estimates for TSE:BHC Lifted by Zacks Research - MarketBeat
2024 Research | Europe Retinal Surgery Devices Market Poised for Growth, Expected to Reach $1.16 Billion by 2032, Driven by Rising Prevalence of Retinal Diseases and Technological Advancements - GlobeNewswire Inc.
Bausch Health (BHC) Reports Next Week: What to Expect - Yahoo Finance
What is Zacks Research's Forecast for BHC Q3 Earnings? - MarketBeat
Zacks Research Has Positive Outlook for TSE:BHC Q3 Earnings - MarketBeat
Bausch Health Companies (BHC) Set to Announce Earnings on Wednesday - MarketBeat
Bausch Health Companies (BHC) Scheduled to Post Earnings on Wednesday - MarketBeat
Contact Lenses Market Forecast: Segments, Drivers, and Growth - openPR
Bausch Health says not considering bankruptcy or insolvency proceeding of any kind - MSN
Non-Invasive Aesthetic Treatment Industry Report 2024, - GlobeNewswire
Non-Invasive Aesthetic Treatment Industry Report 2024, Featuring Profiles of Alma Lasers, Bausch Health Companies, Candela, Cutera, Cynosure Lutronic, Daeyang Medical, Fotona, Galderma and More - Yahoo Finance
Scar Treatment Market to See Booming Growth 2024-2031 | Bausch - openPR
Bausch Health call volume above normal and directionally bullish - Yahoo Finance
Health Care Climbs Slightly Amid Mixed EarningsHealth Care Roundup - Marketscreener.com
Bausch Health Companies (NYSE:BHC) Stock Price Down 2.8%Time to Sell? - MarketBeat
Bausch Health Shares Fall after Rejecting Bondholder Proposals to Restructure Debt - MarketWatch
Bausch Health Companies (NYSE:BHC) Downgraded to "Hold" at StockNews.com - MarketBeat
Stocks to Watch: Netflix, MGP Ingredients, Bausch Health - MarketWatch
Stocks to Watch : Netflix, MGP Ingredients, Bausch Health - Marketscreener.com
Exclusive | Bausch Health Rejects Bondholders’ Debt Proposals, Explores Sale of Vision Care Unit - The Wall Street Journal
Bausch Health Companies Inc Stock (BHC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):